Page 2 - இடம்பெறும் பார்மா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இடம்பெறும் பார்மா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இடம்பெறும் பார்மா Today - Breaking & Trending Today

Ellume nets $232M government contract to produce COVID-19 home tests in U.S.

Feb 2, 2021 10:24am
The 8.5 million self-tests purchased from Ellume will be distributed across the country under the national COVID-19 response policy established on President Biden’s first full day in office last month. (uschools/iStock/Getty Images Plus/Getty Images)
Australian COVID-19 diagnostic maker Ellume has secured a $231.8 million contract from the Biden administration to establish its first production facility in the U.S., and deliver 8.5 million of its at-home tests.
The company’s digital coronavirus test received a landmark FDA green light last December, allowing it to be sold over-the-counter and performed solo, regardless of whether a person is displaying symptoms, and going from swab to result in about 20 minutes. ....

Sean Parsons , Syneos Health , Community Health Leaders , Department Of Defense , Department Of Health , Human Services , National Institutes Of Health , Clinical Research , Clinical Trial Diversity , Four Part Webinar Series , Featuring Pharma , National Institutes , Brisbane Based Ellume , சீன் பார்சன்கள் , சமூக ஆரோக்கியம் தலைவர்கள் , துறை ஆஃப் பாதுகாப்பு , துறை ஆஃப் ஆரோக்கியம் , மனிதன் சேவைகள் , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , மருத்துவ ஆராய்ச்சி , மருத்துவ சோதனை பன்முகத்தன்மை , நான்கு பகுதி வெபினார் தொடர் , இடம்பெறும் பார்மா , தேசிய நிறுவனங்கள் ,

Vanderbilt scientists outsmart an 'undruggable' cancer-driving gene with engineered mutations

Feb 1, 2021 8:30am
Vanderbilt University researchers hope new insights into the interaction between MYC and HCF1 in Burkitt lymphoma will inspire drug development. (PDPics/Pixabay)
The protein produced by the gene MYC performs many important functions during development, but, if it’s reactivated later in life, it can drive deadly cancers.
Scientists at Vanderbilt University have developed a novel way to disrupt MYC by genetically modifying it so it can no longer interact with another protein and drive cancer. The method caused tumors to rapidly shrink in mouse models, the team reported in the journal eLife.
Oncology researchers have been pursuing MYC for decades, but, because it has an unstructured “noodlelike” shape, it has long been considered “undruggable,” said co-author William Tansey, Ph.D., professor of cell and developmental biology and biochemistry at Vanderbilt, in a statement. So Tansey and his team decided to try to disrupt MYC by tar ....

William Tansey , Syneos Health , Community Health Leaders , Clinical Research , Scientists At Vanderbilt University , University Of Pennsylvania , Cold Spring Harbor Laboratory , Ontario Institute For Cancer Research , Vanderbilt University , Clinical Trial Diversity , Four Part Webinar Series , Featuring Pharma , Ontario Institute , Cancer Research , வில்லியம் டான்சி , சமூக ஆரோக்கியம் தலைவர்கள் , மருத்துவ ஆராய்ச்சி , விஞ்ஞானிகள் இல் வாண்டர்பில்ட் பல்கலைக்கழகம் , பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா , குளிர் வசந்த துறைமுகம் ஆய்வகம் , ஆஂடேரியொ நிறுவனம் க்கு புற்றுநோய் ஆராய்ச்சி , வாண்டர்பில்ட் பல்கலைக்கழகம் , மருத்துவ சோதனை பன்முகத்தன்மை , நான்கு பகுதி வெபினார் தொடர் , இடம்பெறும் பார்மா , ஆஂடேரியொ நிறுவனம் ,

WCLC: J&J's bispecific antibody hinders 74% of lung cancers with rare EGFR mutation

Jan 28, 2021 10:45pm
Johnson & Johnson is seeking a nod for amivantamab as a second-line treatment for lung cancer patients with a rare EGFR mutation, but the company is already working on moving the candidate into the front-line setting. (Janssen)
Johnson & Johnson’s EGFR-MET bispecific antibody is padding its case ahead of a potential FDA nod. The drug shrank tumors in 40% of lung cancer patients with a rare EGFR mutation and curbed tumor growth in nearly three-quarters of patients.
The phase 2 data, presented virtually at the World Conference on Lung Cancer (WCLC), come from 81 patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. The patients’ cancer had spread beyond the lungs or couldn’t be treated with surgery and had gotten worse despite taking platinum chemotherapy. ....

Joshua Sabari , Astrazeneca Tagrisso , Syneos Health , Community Health Leaders , York University Langone Perlmutter Cancer Center , Clinical Research , World Conference , Lung Cancer , Clinical Trial Diversity , Four Part Webinar Series , Featuring Pharma , New York University Langone , Perlmutter Cancer Center , South Korea , Johnson Amp , World Conference On Lung Cancer , Non Small Cell Lung Cancer , Egfr Receptor , Targeted Therapies , Bispecific Antibodies , Wclc 21 , ஜோஷுவா சபாரி , சமூக ஆரோக்கியம் தலைவர்கள் , யார்க் பல்கலைக்கழகம் லன்கொனே பேர்ல்முத்தேர் புற்றுநோய் மையம் , மருத்துவ ஆராய்ச்சி , உலகம் மாநாடு ,

Chutes & Ladders—Roivant's Ramaswamy pegs CFO Giles for chief executive role

Ralph Brandenberger,
Ph.D., to senior vice president, technical operations. Brandenberger joined the Nkarta team in 2018 and oversees the company s cell therapy manufacturing operations.
Tracy Dowling as general counsel starting Jan. 25. Dowling will help manage and advise on corporate governance, business development transactions, license agreements, employment law and more. Most recently, Dowling served as associate general counsel at Spark Therapeutics.
Bernard Courtieu as CEO. Courtieu previously joined IntegraGen as CEO in 2007.
Eduardo Bravo,
OncoDNA s interim CEO since July 2020, will remain a consultant to the company s board.
Melanie Ross as chief financial officer, effective immediately. Ross will also serve on the company s board. Most recently, she was group finance director at GVO-B1; prior to that, Ross ....

United Kingdom , United States , Jayanthi Wolf , Vivek Ramaswamy , Matt Gline , Marc Brown , Steve White , Ronald Marcus , Fraiser Kansteiner , Eli Lilly , Melanie Ross , Philip Vickers , Ralph Brandenberger , Jonae Barnes , Todd Fruchterman , Michael Yang , Diego Viacyte , Eduardo Bravo , Brittany Bradrick , Tracy Dowling , Qasim Rizvi , Sumitomo Dainippon , Bernard Courtieu , Cary Pfeffer , Carla Poulson , Jon Lenn ,

One-dose COVID-19 vaccine candidate that can be stored at room temperature prompts immunity in animals

Jan 29, 2021 7:00am
AAVCOVID vaccine candidates from Mass General Brigham elicited immune responses to COVID-19 in mouse models of aging and obesity as well as in nonhuman primates. (Pixabay)
Among the logistical challenges facing public health agencies that are struggling to vaccinate the masses against COVID-19 is that the two mRNA shots on the market, from Moderna and Pfizer, need to be stored at ultra-cold temperatures. Now, an alternative technology for shielding patients from the novel coronavirus one that doesn’t pose that storage challenge is showing early promise.
Two vaccine candidates built from gene-therapy technology and developed by Mass General Brigham scientists elicited strong immune responses in mouse and nonhuman primate models, the researchers reported on the journal preprint site bioRxiv. The team received a grant of up to $2.1 million from the Bill & Melinda Gates Foundation to further develop the vaccine technology, called AAVCOVID. ....

Novarti Zolgensma , Luk Vandenberghe , Grousbeck Gene Therapy Center At Massachusetts Eye , Community Health Leaders , Melinda Gates Foundation , Harvard Medical School , Syneos Health , University Of Pennsylvania , Clinical Research , Mass General Brigham , Clinical Trial Diversity , Four Part Webinar Series , Featuring Pharma , Mass Gen , Grousbeck Gene Therapy Center , Massachusetts Eye , Fierce Biotech , சமூக ஆரோக்கியம் தலைவர்கள் , மெலிண்டா வாயில்கள் அடித்தளம் , ஹார்வர்ட் மருத்துவ பள்ளி , பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா , மருத்துவ ஆராய்ச்சி , நிறை ஜநரல் ப்ரிகாம் , மருத்துவ சோதனை பன்முகத்தன்மை , நான்கு பகுதி வெபினார் தொடர் , இடம்பெறும் பார்மா ,